{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:34:02Z","timestamp":1792614842882,"version":"4.5.0"},"reference-count":165,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2913","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:53:03Z","timestamp":1762433583000},"page":"1-17","source":"Crossref","is-referenced-by-count":17,"title":["Drug resistance in glioblastoma: Challenges, mechanisms and therapeutic strategies (Review)"],"prefix":"10.3892","volume":"24","author":[{"given":"Yash","family":"Durga","sequence":"first","affiliation":[{"name":"Foothill High School, Pleasanton, CA 94588, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Pusapati","sequence":"additional","affiliation":[{"name":"Cancer Biology, Maipl Therapeutics, Scarsdale, NY 10583, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"key20251211105209_b1-MCO-24-1-02913"},{"key":"key20251211105209_b2-MCO-24-1-02913"},{"key":"key20251211105209_b3-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: A review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"key20251211105209_b4-MCO-24-1-02913"},{"key":"key20251211105209_b5-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1113\/jphysiol.1990.sp018243","article-title":"Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study","volume":"429","author":"Butt","year":"1990","journal-title":"J Physiol"},{"issue":"282","key":"key20251211105209_b6-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00282","article-title":"Pericytes and neurovascular function in the healthy and diseased brain","volume":"13","author":"Brown","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"351","key":"key20251211105209_b7-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010351","article-title":"Molecular mechanisms of treatment resistance in glioblastoma","volume":"22","author":"Ou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20251211105209_b8-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b9-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"issue":"318","key":"key20251211105209_b10-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2017.00318","article-title":"Targeting WNT signaling for multifaceted glioblastoma therapy","volume":"11","author":"McCord","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"key20251211105209_b11-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1126\/science.1206936","article-title":"The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence","volume":"334","author":"Alvarez","year":"2011","journal-title":"Science"},{"issue":"12654","key":"key20251211105209_b12-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312654","article-title":"Blood-brain barrier in brain tumors: Biology and clinical relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20251211105209_b13-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0140-6736(63)90681-0","article-title":"Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid","volume":"2","author":"Ommaya","year":"1963","journal-title":"Lancet"},{"key":"key20251211105209_b14-MCO-24-1-02913","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","article-title":"Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"key20251211105209_b15-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3171\/jns.1995.83.6.1029","article-title":"Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy","volume":"83","author":"Siegal","year":"1995","journal-title":"J Neurosurg"},{"key":"key20251211105209_b16-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/j.1476-5381.2012.02103.x","article-title":"The association of statins plus LDL receptor-targeted Liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells","volume":"167","author":"Pinz\u00f3n-Daza","year":"2012","journal-title":"Br J Pharmacol"},{"key":"key20251211105209_b17-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol Pharm"},{"key":"key20251211105209_b18-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.7150\/thno.35892","article-title":"Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model","volume":"9","author":"McDannold","year":"2019","journal-title":"Theranostics"},{"key":"key20251211105209_b19-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1158\/1078-0432.CCR-16-1518","article-title":"Neural stem Cell-based anticancer gene therapy: A First-in-Human study in recurrent High-grade glioma patients","volume":"23","author":"Portnow","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20251211105209_b20-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"40","key":"key20251211105209_b21-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00512-8","article-title":"Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: A comprehensive review","volume":"13","author":"Shen","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"key20251211105209_b22-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20251211105209_b23-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/sj.onc.1209785","article-title":"Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine","volume":"26","author":"Roos","year":"2007","journal-title":"Oncogene"},{"key":"key20251211105209_b24-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","article-title":"Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts","volume":"11","author":"Kitange","year":"2009","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b25-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"S2001","key":"key20251211105209_b26-MCO-24-1-02913","article-title":"Randomized phase II\/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102)","volume":"40 (Suppl 16)","author":"Sarkaria","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20251211105209_b27-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20251211105209_b28-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11060-016-2065-5","article-title":"Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: The GENOM 009 randomized phase II trial","volume":"127","author":"Balana","year":"2016","journal-title":"J Neurooncol"},{"key":"key20251211105209_b29-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.18632\/oncotarget.1302","article-title":"Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma","volume":"4","author":"Shinsato","year":"2013","journal-title":"Oncotarget"},{"key":"key20251211105209_b30-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment","volume":"13","author":"Cahill","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20251211105209_b31-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1179\/1743132814Y.0000000409","article-title":"Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma","volume":"37","author":"Stark","year":"2015","journal-title":"Neurol Res"},{"key":"key20251211105209_b32-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","article-title":"A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy","volume":"66","author":"Hunter","year":"2006","journal-title":"Cancer Res"},{"key":"key20251211105209_b33-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.nec.2020.12.009","article-title":"The role of mismatch repair in glioblastoma multiforme treatment response and resistance","volume":"32","author":"Leelatian","year":"2021","journal-title":"Neurosurg Clin N Am"},{"key":"key20251211105209_b34-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41591-023-02392-7","article-title":"Pembrolizumab in brain metastases of diverse histologies: Phase 2 trial results","volume":"29","author":"Brastianos","year":"2023","journal-title":"Nat Med"},{"key":"key20251211105209_b35-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"issue":"7604","key":"key20251211105209_b36-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147604","article-title":"Survivin inhibition by piperine sensitizes glioblastoma cancer stem cells and leads to better drug response","volume":"23","author":"Warrier","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20251211105209_b37-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20251211105209_b38-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2015.07.013","article-title":"Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells","volume":"367","author":"Munoz","year":"2015","journal-title":"Cancer Lett"},{"issue":"617","key":"key20251211105209_b39-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-617","article-title":"Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme","volume":"13","author":"Oberstadt","year":"2013","journal-title":"BMC Cancer"},{"issue":"373","key":"key20251211105209_b40-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01370-6","article-title":"Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma","volume":"28","author":"Yan","year":"2023","journal-title":"Eur J Med Res"},{"issue":"317","key":"key20251211105209_b41-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12017-y","article-title":"p53\/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme","volume":"24","author":"Meng","year":"2024","journal-title":"BMC Cancer"},{"issue":"3217","key":"key20251211105209_b42-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063217","article-title":"A Review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance","volume":"25","author":"Karve","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"484","key":"key20251211105209_b43-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030484","article-title":"The many facets of therapy resistance and tumor recurrence in glioblastoma","volume":"10","author":"Goenka","year":"2021","journal-title":"Cells"},{"issue":"e412","key":"key20251211105209_b44-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.153","article-title":"BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1\u03b1 stability and MGMT expression","volume":"3","author":"Persano","year":"2012","journal-title":"Cell Death Dis"},{"key":"key20251211105209_b45-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/brain\/awq042","article-title":"A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha","volume":"133","author":"Seidel","year":"2010","journal-title":"Brain"},{"issue":"976356","key":"key20251211105209_b46-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.976356","article-title":"A novel hypoxia-driven gene signature that can predict the prognosis and drug resistance of gliomas","volume":"13","author":"Ren","year":"2022","journal-title":"Front Genet"},{"issue":"1128","key":"key20251211105209_b47-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1176-7","article-title":"Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a\/Bad\/Bax axis","volume":"9","author":"Ge","year":"2018","journal-title":"Cell Death Dis"},{"issue":"S2029","key":"key20251211105209_b48-MCO-24-1-02913","article-title":"Phase 1\/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure","volume":"32 (15_Suppl)","author":"Brenner","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20251211105209_b49-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11060-023-04456-7","article-title":"Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma","volume":"165","author":"Strowd","year":"2023","journal-title":"J Neurooncol"},{"key":"key20251211105209_b50-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1158\/2767-9764.CRC-22-0433","article-title":"Dodecafluoropentane emulsion as a radiosensitizer in glioblastoma multiforme","volume":"3","author":"Lickliter","year":"2023","journal-title":"Cancer Res Commun"},{"key":"key20251211105209_b51-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s10637-013-0048-3","article-title":"Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors","volume":"32","author":"Jeong","year":"2014","journal-title":"Invest New Drugs"},{"issue":"506","key":"key20251211105209_b52-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/nature11903","article-title":"Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"494","author":"Network","year":"2013","journal-title":"Nature"},{"key":"key20251211105209_b53-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/cns.14.13","article-title":"PDK1: A new therapeutic target for glioblastoma?","volume":"3","author":"Velpula","year":"2014","journal-title":"CNS Oncol"},{"key":"key20251211105209_b54-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"35639","DOI":"10.18632\/oncotarget.16767","article-title":"Metabolic targeting of EGFRvIII\/PDK1 axis in temozolomide resistant glioblastoma","volume":"8","author":"Velpula","year":"2017","journal-title":"Oncotarget"},{"key":"key20251211105209_b55-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro Oncol"},{"issue":"144","key":"key20251211105209_b56-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00144","article-title":"CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment","volume":"8","author":"W\u00fcrth","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"key20251211105209_b57-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"646","DOI":"10.18632\/oncotarget.322","article-title":"The NF\u03baB pathway: A therapeutic target in glioblastoma","volume":"2","author":"Nogueira","year":"2011","journal-title":"Oncotarget"},{"key":"key20251211105209_b58-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/1541-7786.MCR-13-0650","article-title":"PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD","volume":"12","author":"Pareja","year":"2014","journal-title":"Mol Cancer Res"},{"issue":"7403747","key":"key20251211105209_b59-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7403747","article-title":"Apoptotic signaling pathways in glioblastoma and therapeutic implications","volume":"2017","author":"Vald\u00e9s-Rives","year":"2017","journal-title":"BioMed Res Int"},{"issue":"9956","key":"key20251211105209_b60-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/srep09956","article-title":"Combined inhibition of AKT\/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells","volume":"5","author":"Daniele","year":"2015","journal-title":"Sci Rep"},{"key":"key20251211105209_b61-MCO-24-1-02913","first-page":"2163","article-title":"Escape of U251 glioma cells from temozolomide-induced senescence was modulated by CDK1\/survivin signaling","volume":"9","author":"Song","year":"2017","journal-title":"Am J Transl Res"},{"key":"key20251211105209_b62-MCO-24-1-02913","first-page":"1845","article-title":"The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line","volume":"33","author":"Josset","year":"2013","journal-title":"Anticancer Res"},{"key":"key20251211105209_b63-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.3892\/or.2019.7095","article-title":"TRPC5-induced autophagy promotes the TMZ-resistance of glioma cells via the CAMMK\u03b2\/AMPK\u03b1\/mTOR pathway","volume":"41","author":"Zou","year":"2019","journal-title":"Oncol Rep"},{"issue":"2047","key":"key20251211105209_b64-MCO-24-1-02913","article-title":"Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results","volume":"40 (16_suppl)","author":"Wen","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20251211105209_b65-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/neuonc\/nov083","article-title":"Phase I dose-escalation study of the PI3K\/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma","volume":"17","author":"Wen","year":"2015","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b66-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2015.07.007","article-title":"NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells","volume":"367","author":"Yu","year":"2015","journal-title":"Cancer Lett"},{"key":"key20251211105209_b67-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.biopha.2018.06.084","article-title":"MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway","volume":"106","author":"Xu","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key20251211105209_b68-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.freeradbiomed.2011.10.487","article-title":"Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy","volume":"52","author":"Lin","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"69","key":"key20251211105209_b69-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0517-y","article-title":"p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ","volume":"32","author":"Ma","year":"2015","journal-title":"Med Oncol"},{"key":"key20251211105209_b70-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/neuonc\/noae028","article-title":"Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide","volume":"26","author":"Cheng","year":"2024","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b71-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","article-title":"Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma","volume":"101","author":"Reardon","year":"2011","journal-title":"J Neurooncol"},{"key":"key20251211105209_b72-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1002\/cncr.25275","article-title":"Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer"},{"key":"key20251211105209_b73-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/cdr.2020.79","article-title":"Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"key20251211105209_b74-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/neuonc\/not104","article-title":"Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a\/glycogen synthase-3 kinase\/\u03b2-catenin pathway","volume":"15","author":"Riganti","year":"2013","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b75-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3892\/or.2017.5459","article-title":"FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of \u03b2-catenin nuclear accumulation","volume":"37","author":"Xu","year":"2017","journal-title":"Oncol Rep"},{"issue":"eaay7522","key":"key20251211105209_b76-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay7522","article-title":"Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma","volume":"12","author":"Huang","year":"2020","journal-title":"Sci Transl Med"},{"issue":"8904","key":"key20251211105209_b77-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9904","article-title":"Wnt\/\u03b2-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance","volume":"6","author":"Wickstr\u00f6m","year":"2015","journal-title":"Nat Commun"},{"key":"key20251211105209_b78-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10565-019-09502-7","article-title":"Temozolomide induces activation of Wnt\/\u03b2-catenin signaling in glioma cells via PI3K\/Akt pathway: Implications in glioma therapy","volume":"36","author":"Tomar","year":"2020","journal-title":"Cell Biol Toxicol"},{"key":"key20251211105209_b79-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neulet.2017.07.057","article-title":"FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling","volume":"657","author":"Lu","year":"2017","journal-title":"Neurosci Lett"},{"key":"key20251211105209_b80-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.lfs.2019.04.023","article-title":"miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt\/\u03b2-catenin signaling via targeting SOX2","volume":"226","author":"Luo","year":"2019","journal-title":"Life Sci"},{"issue":"394","key":"key20251211105209_b81-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0343-1","article-title":"miR-129-5p targets Wnt5a to block PKC\/ERK\/NF-\u03baB and JNK pathways in glioblastoma","volume":"9","author":"Zeng","year":"2018","journal-title":"Cell Death Dis"},{"key":"key20251211105209_b82-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2013.08.043","article-title":"Blockage of a miR-21\/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas","volume":"342","author":"Zhang","year":"2014","journal-title":"Cancer Lett"},{"issue":"12885","key":"key20251211105209_b83-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12885","article-title":"A regulatory circuit of miR-125b\/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways","volume":"7","author":"Huang","year":"2016","journal-title":"Nat Commun"},{"issue":"e0225913","key":"key20251211105209_b84-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225913","article-title":"IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt\/\u03b2-catenin pathway","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"key":"key20251211105209_b85-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/NEN.0000000000000227","article-title":"Pharmacologic wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells","volume":"74","author":"Kahlert","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"key20251211105209_b86-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/labinvest.2011.161","article-title":"Wnt activation is implicated in glioblastoma radioresistance","volume":"92","author":"Kim","year":"2012","journal-title":"Lab Invest"},{"key":"key20251211105209_b87-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1535-7163.MCT-12-1176-T","article-title":"Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells","volume":"12","author":"De Robertis","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"CT523","key":"key20251211105209_b88-MCO-24-1-02913","article-title":"Abstract CT523: An open-label, multicenter, phase 1b\/2 Study of E7386 (Wnt\/\u03b2-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors","volume":"82 (Suppl)","author":"Yoshino","year":"2022","journal-title":"Cancer Res"},{"key":"key20251211105209_b89-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1101\/gad.176800.111","article-title":"The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma","volume":"25","author":"Bhat","year":"2011","journal-title":"Genes Dev"},{"key":"key20251211105209_b90-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/NEN.0b013e31821ff8d8","article-title":"Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth","volume":"70","author":"Orr","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"key20251211105209_b91-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.bbrc.2015.05.115","article-title":"TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells","volume":"463","author":"Tian","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"13431","key":"key20251211105209_b92-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413431","article-title":"Hippo pathway in regulating drug resistance of glioblastoma","volume":"22","author":"Casati","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20251211105209_b93-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.01.076","article-title":"Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation","volume":"26","author":"Minata","year":"2019","journal-title":"Cell Rep"},{"key":"key20251211105209_b94-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-20-0018","article-title":"YAP\/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma","volume":"27","author":"Vigneswaran","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20251211105209_b95-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/noac019","article-title":"Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma","volume":"24","author":"Read","year":"2022","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b96-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat Cancer"},{"issue":"S1671","key":"key20251211105209_b97-MCO-24-1-02913","article-title":"Abstract 1671: Discovery of ETS-003, a potent and selective YAP\/TAZ-TEAD PPI inhibitor with broad anti-tumor activity in Hippo-YAP aberrant cancers","volume":"83 (Suppl)","author":"Lu","year":"2023","journal-title":"Cancer Res"},{"key":"key20251211105209_b98-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat Cancer"},{"key":"key20251211105209_b99-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s11010-021-04221-2","article-title":"Exosomal noncoding RNAs: Key players in glioblastoma drug resistance","volume":"476","author":"Movahedpour","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"key20251211105209_b100-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cam4.775","article-title":"MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics","volume":"5","author":"Shea","year":"2016","journal-title":"Cancer Med"},{"key":"key20251211105209_b101-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"50229","DOI":"10.18632\/oncotarget.10357","article-title":"miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely","volume":"7","author":"Xiao","year":"2016","journal-title":"Oncotarget"},{"key":"key20251211105209_b102-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1093\/hmg\/ddx323","article-title":"High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors","volume":"26","author":"Cunha","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"76","key":"key20251211105209_b103-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01832-8","article-title":"Long noncoding RNA H19: Functions and mechanisms in regulating programmed cell death in cancer","volume":"10","author":"Xia","year":"2024","journal-title":"Cell Death Discov"},{"issue":"166","key":"key20251211105209_b104-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1139-6","article-title":"Exosomal transfer of long Non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma","volume":"38","author":"Zhang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20251211105209_b105-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1159\/000478917","article-title":"Long Non-Coding RNA MALAT1 decreases the sensitivity of resistant glioblastoma cell lines to temozolomide","volume":"42","author":"Li","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"63","key":"key20251211105209_b106-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0606-4","article-title":"MALAT1: A druggable long non-coding RNA for targeted anti-cancer approaches","volume":"11","author":"Amodio","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"217","key":"key20251211105209_b107-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00217","article-title":"Novel function of lncRNA ADAMTS9-AS2 in promoting temozolomide resistance in glioblastoma via upregulating the FUS\/MDM2 ubiquitination axis","volume":"7","author":"Yan","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"key20251211105209_b108-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/jcb.25910","article-title":"LncRNA CASC2 Interacts With miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway","volume":"118","author":"Liao","year":"2017","journal-title":"J Cell Biochem"},{"issue":"2130","key":"key20251211105209_b109-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142130","article-title":"Role of circular RNA in brain tumor development","volume":"11","author":"Ahmed","year":"2022","journal-title":"Cells"},{"key":"key20251211105209_b110-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.03.002","article-title":"Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma","volume":"479","author":"Ding","year":"2020","journal-title":"Cancer Lett"},{"key":"key20251211105209_b111-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/cbr.2019.3492","article-title":"Exosomal circ-HIPK3 facilitates tumor progression and temozolomide resistance by regulating miR-421\/ZIC5 axis in glioma","volume":"36","author":"Han","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"issue":"1547889","key":"key20251211105209_b112-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1547889","article-title":"The dual role of circHIPK3 in cancer and its implications for multiple drugs resistance: A systematic review and computational approach","volume":"15","author":"Campelo","year":"2025","journal-title":"Front Oncol"},{"key":"key20251211105209_b113-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s11011-022-01069-3","article-title":"Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma","volume":"37","author":"Li","year":"2022","journal-title":"Metab Brain Dis"},{"key":"key20251211105209_b114-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/neuonc\/noaa214","article-title":"EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS\/MEK1\/ERK1-2 signaling","volume":"23","author":"Wei","year":"2021","journal-title":"Neuro Oncol"},{"issue":"101","key":"key20251211105209_b115-MCO-24-1-02913","article-title":"Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294","volume":"45","author":"Hua","year":"2020","journal-title":"J Biosci"},{"key":"key20251211105209_b116-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.7150\/thno.92703","article-title":"CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis\/TMZ resistance in the mesenchymal subtype of glioblastoma","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"key20251211105209_b117-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijrobp.2017.02.223","article-title":"Treatment of gliomas: A changing landscape","volume":"98","author":"Halasz","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251211105209_b118-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ijrobp.2009.03.013","article-title":"A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal High-grade gliomas","volume":"76","author":"Shaffer","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251211105209_b119-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.prro.2015.12.001","article-title":"Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma","volume":"6","author":"Wang","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"key20251211105209_b120-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/neuonc\/noab288","article-title":"Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma","volume":"24","author":"Gu","year":"2022","journal-title":"Neuro Oncol"},{"issue":"eabc7275","key":"key20251211105209_b121-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc7275","article-title":"Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice","volume":"13","author":"Fang","year":"2021","journal-title":"Sci Transl Med"},{"issue":"101988","key":"key20251211105209_b122-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101988","article-title":"Fractionated radiation therapy alters energy metabolism and induces cellular quiescence exit in patient-derived orthotopic xenograft models of high-grade glioma","volume":"45","author":"Huang","year":"2024","journal-title":"Transl Oncol"},{"issue":"e136098","key":"key20251211105209_b123-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136098","article-title":"N-cadherin upregulation mediates adaptive radioresistance in glioblastoma","volume":"131","author":"Osuka","year":"2021","journal-title":"J Clin Invest"},{"issue":"e148717","key":"key20251211105209_b124-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.148717","article-title":"An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases","volume":"7","author":"Stackhouse","year":"2022","journal-title":"JCI Insight"},{"issue":"60","key":"key20251211105209_b125-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"key20251211105209_b126-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.drudis.2017.10.010","article-title":"Gemcitabine and glioblastoma: Challenges and current perspectives","volume":"23","author":"Bastiancich","year":"2018","journal-title":"Drug Discov Today"},{"issue":"3664","key":"key20251211105209_b127-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22022-4","article-title":"Radiosensitization effect of talazoparib, a parp inhibitor, on glioblastoma stem cells exposed to low and high linear energy transfer radiation","volume":"8","author":"Lesueur","year":"2018","journal-title":"Sci Rep"},{"key":"key20251211105209_b128-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2003.07.006","article-title":"Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (\u2018Iressa\u2019)","volume":"202","author":"Stea","year":"2003","journal-title":"Cancer Lett"},{"issue":"e167081","key":"key20251211105209_b129-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167081","article-title":"Quisinostat is a brain-penetrant radiosensitizer in glioblastoma","volume":"8","author":"Lo Cascio","year":"2023","journal-title":"JCI Insight"},{"key":"key20251211105209_b130-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: Results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b131-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1080\/15548627.2020.1816343","article-title":"Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: A phase IB trial","volume":"17","author":"Compter","year":"2021","journal-title":"Autophagy"},{"key":"key20251211105209_b132-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.1073\/pnas.1808945115","article-title":"Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism","volume":"115","author":"Benej","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2511","key":"key20251211105209_b133-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092511","article-title":"Radioresistance in glioblastoma and the development of radiosensitizers","volume":"12","author":"Ali","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20251211105209_b134-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"key20251211105209_b135-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.1114033109","article-title":"Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response","volume":"109","author":"Szerlip","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20251211105209_b136-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41388-022-02294-x","article-title":"PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1\/p38MAPK signalling","volume":"41","author":"Lane","year":"2022","journal-title":"Oncogene"},{"key":"key20251211105209_b137-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"53047","DOI":"10.18632\/oncotarget.10132","article-title":"PDGFR\u03b1 depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals","volume":"7","author":"Cenciarelli","year":"2016","journal-title":"Oncotarget"},{"key":"key20251211105209_b138-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccell.2025.02.018","article-title":"Effective targeting of PDGFRA-altered high-grade glioma with avapritinib","volume":"43","author":"Mayr","year":"2025","journal-title":"Cancer Cell"},{"key":"key20251211105209_b139-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"key20251211105209_b140-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 Phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20251211105209_b141-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"key20251211105209_b142-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"issue":"2316","key":"key20251211105209_b143-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042316","article-title":"Epidermal growth factor receptor inhibitors in glioblastoma: Current status and future possibilities","volume":"25","author":"Ezzati","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20251211105209_b144-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/nn.4584","article-title":"Primary resistance to EGFR inhibition in glioblastoma is mediated by a TNF-JNK-Axl-ERK signaling axis","volume":"20","author":"Guo","year":"2017","journal-title":"Nat Neurosci"},{"key":"key20251211105209_b145-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","article-title":"Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma","volume":"23","author":"Marin","year":"2021","journal-title":"Neuro Oncol"},{"key":"key20251211105209_b146-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/bjc.2014.209","article-title":"Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma","volume":"110","author":"Hottinger","year":"2014","journal-title":"Br J Cancer"},{"key":"key20251211105209_b147-MCO-24-1-02913","first-page":"3475","article-title":"Sorafenib increases tumor treating Fields-induced cell death in glioblastoma by inhibiting STAT3","volume":"10","author":"Kim","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"1262","key":"key20251211105209_b148-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091262","article-title":"BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors","volume":"11","author":"Schreck","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"600","key":"key20251211105209_b149-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030600","article-title":"Advancements, challenges, and future directions in tackling glioblastoma resistance to small kinase inhibitors","volume":"14","author":"Fabro","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20251211105209_b150-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/01.WNL.0000158654.07080.B0","article-title":"EGFR tyrosine kinase domain mutations in human gliomas","volume":"64","author":"Marie","year":"2005","journal-title":"Neurology"},{"key":"key20251211105209_b151-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"key20251211105209_b152-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"key":"key20251211105209_b153-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1016\/j.celrep.2020.02.014","article-title":"Glioblastoma cell resistance to EGFR and MET inhibition can be overcome via blockade of FGFR-SPRY2 bypass signaling","volume":"30","author":"Day","year":"2020","journal-title":"Cell Rep"},{"key":"key20251211105209_b154-MCO-24-1-02913","first-page":"200","article-title":"Insulin-like growth factor receptor I mediates resistance to Anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling","volume":"62","author":"Chakravarti","year":"2002","journal-title":"Cancer Res"},{"key":"key20251211105209_b155-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer"},{"key":"key20251211105209_b156-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1158\/2767-9764.CRC-22-0436","article-title":"Multicenter Phase II trial of the PARP inhibitor olaparib in recurrent IDH1- and IDH2-mutant glioma","volume":"3","author":"Fanucci","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"149","key":"key20251211105209_b157-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00646-2","article-title":"Treatment of IDH-mutant glioma in the INDIGO era","volume":"8","author":"Lin","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"key20251211105209_b158-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"6938","key":"key20251211105209_b159-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun"},{"issue":"887781","key":"key20251211105209_b160-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887781","article-title":"The role of myeloid cells in GBM immunosuppression","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"2070","key":"key20251211105209_b161-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092070","article-title":"Glioblastoma Embryonic-like stem cells exhibit immune-evasive phenotype","volume":"14","author":"Ses\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"e147552","key":"key20251211105209_b162-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147552","article-title":"Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma","volume":"131","author":"Chen","year":"2021","journal-title":"J Clin Invest"},{"key":"key20251211105209_b163-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat Med"},{"issue":"217","key":"key20251211105209_b164-MCO-24-1-02913","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8654","article-title":"Heterogeneity and individualized treatment of microenvironment in glioblastoma (review)","volume":"50","author":"Kang","year":"2023","journal-title":"Oncol Rep"},{"key":"key20251211105209_b165-MCO-24-1-02913","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11060-019-03172-5","article-title":"Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment","volume":"143","author":"Wu","year":"2019","journal-title":"J Neurooncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:52:21Z","timestamp":1765443141000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":165,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2913","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}